Finacea (Intendis Inc.)


Welcome to the PulseAid listing for the Finacea drug offered from Intendis Inc.. This Decreased Protein Synthesis [PE],Decreased Sebaceous Gland Activity [PE] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Intendis Inc.
NON-PROPRIETARY NAME: azelaic acid
SUBSTANCE NAME: AZELAIC ACID
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Decreased Protein Synthesis [PE],Decreased Sebaceous Gland Activity [PE]
ROUTE: TOPICAL
DOSAGE FORM: GEL
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2004-12-24
END MARKETING DATE: 0000-00-00


Finacea HUMAN PRESCRIPTION DRUG Details:

Item DescriptionFinacea from Intendis Inc.
LABELER NAME: Intendis Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 0.15(g/g)
START MARKETING DATE: 2004-12-24
END MARKETING DATE: 0000-00-00
PRODUCT ID: 10922-825_a7594a20-f46e-4b33-91d5-410cc5e97b8d
PRODUCT NDC: 10922-825
APPLICATION NUMBER: NDA021470

Other AZELAIC ACID Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Allergan, Inc.AZELEX
Alvogen, Inc.Azelaic Acid
Bayer HealthCare Pharmaceuticals Inc.Finacea
Intendis Inc.Finacea
Physicians Total Care, Inc.Finacea